AMRI licenses Teewinot's cannabinoid analytical standard production tech

By Gareth Macdonald

- Last updated on GMT


Related tags Research Technology

AMRI has licensed technology needed to make an analytical standard drug firms working with cannabinoids can use for research and quality control.

The technology used to make the CBCA analytical standard was developed by Teewinot Life Sciences.

Teewinot CEO Jeffrey Korentur told us “researchers will be able to use the standard validate and confirm that the compound they are using either is, or is not, CBCA. Standards may have other uses in research and development including preliminary efficacy studies​.”

He added that: “AMRI is licensed to use our technology to manufacture and sell the CBCA analytical standard​.”

Teewinot has a suite of biosynthetic technologies it uses to make cannabinoid-based compounds in micro-organisms.

The idea is that the approach is faster and more consistent than plant-based production.


The agreement with AMRI is seperate to the deal Teewinot has with the US contractor to scale up the cannabinoid production process.

Korentur told us: “Our scale up is in progress now, and we anticipate being able to produce kilogram quantities of GMP manufactured cannabinoids by Q1 2017​.”

Tech license

News of the deal comes a week after Florida-based Teewinot licensed rights to its cannabinoid active pharmaceutical ingredient (API) manufacturing technology to Nemus Biosciences.

That agreement was signed days after Teewinot’s Ireland-based subsidiary, Full Spectrum Laboratories, was granted a US patent​ for the technology. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more